Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

User Evaluation of the MiniMed 640G Insulin Pump

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01991548
Recruitment Status : Completed
First Posted : November 25, 2013
Results First Posted : May 15, 2017
Last Update Posted : May 15, 2017
Information provided by (Responsible Party):
Medtronic Diabetes

Brief Summary:

This four center international study will include two United Kingdom National Health Service centers, and two centers in Melbourne, Australia. The objective of the study is to evaluate subject acceptance of a new insulin pump and transmitter together with the accompanying training materials. Descriptive data from participant questionnaires and device uploads will be evaluated.

Pediatric subjects between the ages of 7 - 18 years and adults from the age of 19 years of age upwards, who currently use an insulin pump in the management of their type 1 or type 2 diabetes, will be invited to participate. Each subject will be trained on the study device and then use it for approximately four weeks. During this time there will be three in-clinic visits and four follow-up phone calls, scheduled at the subjects' convenience. At the end of this period, they will revert back to their original insulin pump and complete a questionnaire on the study pump training materials, features and usability.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Type 2 Diabetes Device: MiniMed® 640G Insulin Pump and Guardian® Link Transmitter Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A User Evaluation of the MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
Study Start Date : November 2013
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Diabetic participants with study devices Device: MiniMed® 640G Insulin Pump and Guardian® Link Transmitter

Primary Outcome Measures :
  1. User Acceptance of the New MiniMed 640G Insulin Pump and Guardian Link Transmitter [ Time Frame: Four weeks of pump wear ]
    Descriptive summary will be used to characterize the results of the study questionnaires. The questionnaire will use a Likert scale (rating of 1 to 7) to assess subject acceptance of the MiniMed 640G, Guardian Link Transmitter, and the training materials. A response of 4 or greater will be considered positive on a Likert scale for training materials and product acceptance.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   7 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Criteria for Inclusion: A subject is eligible for the user evaluation study if all of the following criteria are met:

  1. Subject is 7 years or older at time of screening
  2. Subject is current insulin pump user for at least 3 months
  3. Subject has the following CGM experience as determined by the Investigator:

    • Has experience and is able to insert/change sensor by herself/himself and
    • Has experience and can recharge the transmitter and
    • Has experience and can read sensor data in real-time on her/his pump screen
  4. Subject/legal representative has signed a Patient Informed Consent and is willing to comply with the study procedures;
  5. Subject is willing to complete study questionnaires throughout the study
  6. Must have the following clinical diagnosis:

1. Type 1 diabetes, for a minimum of 6 months prior to enrollment

Criteria for Exclusion: A subject is excluded from the user evaluation if any of the following criteria are met:

  1. Female subject has a positive urine pregnancy screening test.
  2. Female subject who plans to become pregnant during the course of study. If a woman becomes pregnant during participation, she will be withdrawn
  3. Subject has any condition that, in the opinion of the Investigator or qualified Investigational Centre staff, may preclude him/her from participating in the study and completing study related procedures.
  4. Subject has impaired vision or hearing problems that could compromise the handling of the device as determined by Investigator or qualified Investigational Centre staff
  5. Subject is unable to tolerate tape adhesive in the area of sensor placement
  6. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g. psoriasis, rash, Staphylococcus infection)
  7. Subject has travel plans which would make it difficult for the subject to attend on-site study visits as scheduled
  8. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks (CEP267 User Evaluation is not included in this exclusion criteria).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01991548

Layout table for location information
St Vincent Hospital and The University of Melbourne
Fitzroy, Australia, 3050
The Royal Melbourne Hospital
Patkville, Australia, 3050
United Kingdom
University College Hospital
London, United Kingdom, NW1 2PG
King's College London
London, United Kingdom, SE5 9NU
Sponsors and Collaborators
Medtronic Diabetes

Layout table for additonal information
Responsible Party: Medtronic Diabetes Identifier: NCT01991548    
Other Study ID Numbers: CEP284
First Posted: November 25, 2013    Key Record Dates
Results First Posted: May 15, 2017
Last Update Posted: May 15, 2017
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Medtronic Diabetes:
Insulin pump
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs